I don't think MSB is sending cells to Japan. The product in Japan is Alofisel which I understand is from Tigenix. They only pay royalties to MSB because of MSB patents. Otherwise it's their own product. Still means royalties for MSB if they're successful as MSB has gone on record as saying they have patents covering ARDS. Still a win, bearing in mind this was not a royalty stream on the horizon 6 months ago. Happy to be corrected.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-495
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.41 |
Change
0.620(34.6%) |
Mkt cap ! $3.084B | |||
| Open | High | Low | Value | Volume |
| $1.90 | $2.48 | $1.90 | $58.82M | 25.68M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 100915 | $2.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.41 | 99 | 1 |
View Market Depth
| Last trade - 16.12pm 18/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |